INMB · INmune Bio Inc
United States · RS rating 21 · As of 2026-11-03
| Price | 1.32 USD |
|---|---|
| 1-day change | -4.3% |
| RS rating (overall / 1M / 3M / 12M) | 21 / 11 / 20 / 32 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 24 / 18 / 53 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +75.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +47.4% |
| Market cap (USD) | $36.7M |